Compare Nasdaq100 ETF (QQQ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Zoetis Inc — how do they compare? Nasdaq100 ETF trades at $705.1, while Zoetis Inc trades at $74.04 (market cap $31.59B). The key difference: Zoetis Inc pays a 2.81% dividend while Nasdaq100 ETF pays none, and Nasdaq100 ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| QQQ | ZTS | |
|---|---|---|
52-Week High | $746.16 | $156.76 |
52-Week Low | $553.88 | $71.91 |
Market Cap | — | $31.59B |
Sector | — | Health |
Enterprise Value | — | $38.89B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $708.97, up 1.96% over the past 24 hours, with technical indicators signaling a bearish trend overall despite a neutral oscillator reading. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights institutional position adjustments and comparisons with competing tech-focused ETFs.
Outlook remains divided; potential exists from tech sector strength and AI-driven growth, but risks include high concentration in tech stocks and market volatility. Investors should weigh the bearish technical signals against long-term growth prospects in the Nasdaq-100 index.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
